BeOne Medicines Q1 Earnings Call Highlights

Key Points

• Strong Q1 results and raised guidance: Product revenue was $1.5 billion (up 34% YoY) with BRUKINSA sales of $1.1 billion, GAAP diluted EPS of $1.96, and management raised 2026 revenue guidance by $100 million to a range of $6.3–$6.5 billion.
• BRUKINSA commercial and clinical leadership: Management called BRUKINSA the foundational BTK inhibitor after Q1 sales up 38% and cited head-to-head superiority versus ibrutinib (ALPINE), while positioning data and IRC-reviewed endpoints to defend its competitive claims.
• Pipeline inflection with hematology and solid-tumor progress: BeOne has >60 upcoming ASCO/EHA abstracts, is advancing sonrotoclax (designed as more potent/selective than venetoclax) in combination with BRUKINSA, and reported a BTK CDAC showing a 94.4% ORR at the recommended dose with a potential accelerated-approval filing in H2 2026, alongside late-stage momentum in multiple solid-tumor programs.

BeOne Medicines NASDAQ: ONC reported first-quarter 2026 results that management said reflected “strong execution across the business” and prompted the company to raise its full-year revenue outlook. Co-founder, Chairman and CEO John Oyler said the company entered 2026 with “tremendous momentum,” citing product revenue growth, GAAP earnings per ADS, and continued progress across its hematology franchise and solid tumor pipeline.

The company highlighted a large upcoming data slate, noting more than 60 abstract acceptances across ASCO and EHA, including proof-of-concept data from three solid tumor programs moving into late-stage clinical trials.

Commercial performance led by BRUKINSA

Oyler emphasized the commercial and clinical trajectory of BRUKINSA, which he described as having “firmly established itself as the foundational BTK inhibitor.” BRUKINSA posted first-quarter sales of $1.1 billion, representing 38% growth, and the company said it is seeing strong performance “in all markets and all indications.”

Discussing clinical evidence, Oyler pointed to data presented at ASH 2025 in frontline chronic lymphocytic leukemia (CLL), including six-year progression-free survival of 74% and overall survival of 84%, with adjusted figures of 77% and 87%, respectively, when accounting for COVID. He also highlighted long-term landmark progression-free survival comparisons across trials, while noting cross-trial limitations.

Oyler said BRUKINSA is “the only BTK inhibitor that has demonstrated superiority on efficacy versus ibrutinib in a head-to-head trial,” referencing ALPINE results with a hazard ratio of 0.69 and a P value of 0.001. During Q&A, Chief Medical Officer for Hematology Amit Aggarwal addressed competitor claims around pirtobrutinib, arguing that head-to-head superiority has not been demonstrated and stressing the importance of independent review committee (IRC) assessments in open-label studies. Aggarwal said BRUKINSA “remains the only BTK inhibitor to have shown clear superiority.”

Sonrotoclax and BTK CDAC development updates

BeOne also detailed its next-generation BCL-2 inhibitor, sonrotoclax (referred to as “Sonro”), which Oyler said was designed to be “14x more potent and 6x more selective than venetoclax,” with a shorter half-life intended to minimize drug accumulation. Oyler said sonrotoclax’s “true transformative potential lies in combination with BRUKINSA,” and the company plans to share updated combination data at ASCO.

In Q&A, Aggarwal discussed the CELESTIAL-301 study design, describing “dual primary endpoints” of undetectable minimal residual disease (uMRD) at end of treatment and progression-free survival (PFS). He said PFS is the “traditional regulatory endpoint” and “base case” for filing, while uMRD is not currently accepted as a regulatory endpoint. Aggarwal said an IDMC review of uMRD across arms is expected in Q3, with disclosure planned “at the next proximate opportunity,” and that the study would continue to the PFS readout without changes to conduct regardless of uMRD outcome.

The company also highlighted progress for its BTK CDAC (a degrader), which Oyler described as “first in class” with “complete BTK degradation” and broad BTK mutation coverage. He said data presented at ASH 2025 showed efficacy in heavily pretreated patients, including those with resistance mutations to covalent and non-covalent BTK inhibitors, and cited a 94.4% overall response rate at a recommended 200 mg dose in a phase I-II study. Management reiterated guidance toward a potential accelerated approval submission in the U.S. for relapsed/refractory CLL in the second half of 2026.

Asked about an accelerated approval efficacy hurdle, Aggarwal said the benchmark is evolving and that the company is “looking at a benchmark of somewhere between 50%-70%, depending on the population.” General Manager of North America Matt Shaulis said the company expects a “relatively robust” launch ramp with a “typical S-shaped uptake curve,” noting a “well-prepared market.” Oyler added that the CDAC and sonrotoclax launches would largely leverage BeOne’s existing commercial infrastructure.

Q1 financial results and updated 2026 guidance

CFO Aaron Rosenberg reported product revenue of $1.5 billion in the quarter, up 34% year over year. BRUKINSA global revenues were $1.1 billion, while U.S. BRUKINSA sales were $761 million, “principally driven by volume growth of approximately 28% versus Q1 2025.” Rosenberg said U.S. results included a mid-single-digit pricing benefit year over year and “non-recurring gross to net favorability of approximately $20 million,” while the company continues to expect “relatively stable pricing in 2026.” He also noted typical first-quarter seasonality in the BTK inhibitor class, including inventory dynamics and one fewer shipping week.

Rosenberg said demand signals improved in March and carried into April, supporting confidence in U.S. performance for the year. TEVIMBRA revenue increased 20%, with management citing sustained market leadership in China and growth contributions from launch markets outside of China. In-license and other products grew 27% year over year, including what Rosenberg called robust performance from the company’s Amgen in-license portfolio. XGEVA contributed $90 million, though Rosenberg noted several biosimilar entrants filed for approval in April, which “could lead to enhanced competition.”

By geography, the company said:

• United States: $766 million revenue, up 36% year over year
• China: $465 million revenue, up 17% (including 5% driven by foreign exchange)
• Europe: $91 million revenue, up 64% (with foreign exchange contributing about 11% of growth)
• Rest of world: up 104%, driven by expansions and launches including Japan and Brazil

Gross margin improved to 89% from about 85% a year ago, which Rosenberg attributed to product mix, price, and cost efficiencies. Operating expenses rose 16% to $1.1 billion as the company invested in commercial growth and pipeline advancement. Income from operations was $250 million, up from $11 million in the prior-year period. Net income totaled $227 million, with GAAP diluted earnings per ADS of $1.96. On a non-GAAP basis, operating income was $414 million and non-GAAP net income was $375 million, or $3.24 per diluted ADS. Free cash flow was $161 million.

Based on first-quarter performance and recent trends, BeOne raised its 2026 revenue guidance by $100 million to a range of $6.3 billion to $6.5 billion. GAAP operating expense guidance was unchanged at $4.7 billion to $4.9 billion, while GAAP operating income guidance was updated to $750 million to $850 million. Rosenberg said the company anticipates “modest full-year initial contributions” from launches of zanidatamab and sonrotoclax.

Solid tumor pipeline and ASCO focus

President and Global Head of R&D Wang Lai said 2026 “marks a true inflection year” for BeOne’s solid tumor portfolio, with several programs moving toward registration. He cited progress including TEVIMBRA receiving U.S. priority review in HER2-positive gastric cancer, activation of phase III sites for the company’s CDK4 inhibitor, and a potentially pivotal hepatocellular carcinoma (HCC) study enrolling for its GPC3x4-1BB bispecific.

Lai said the GPC3x4-1BB program moved from first-in-human dosing to enrolling the first patient in a potentially registrational study in 19 months. He said the company has enrolled more than 200 patients in 20 months and that the program has received FDA Fast Track and Orphan Drug Designations. In response to questions on the pivotal HCC study, Lai said BeOne is discussing the efficacy “bar” with health authorities and will present phase I data at ASCO, with additional updates at an oral presentation and an investor event.

For the CDK4 inhibitor, Chief Medical Officer for Solid Tumors Mark Lanasa said BeOne will present updated data at ASCO from about 60 frontline stage 4 breast cancer patients treated in combination with letrozole. Lanasa said the company plans to show a strong response rate across doses tested for phase III dose selection, along with early data suggesting food may improve gastrointestinal tolerability. He added that PFS maturity remains low given expected frontline PFS exceeding two years.

Lai also discussed an external innovation move: an exclusive option to license a PD-1/VEGF/CTLA-4 trispecific (BON-110, previously HH-160), expected to enter the clinic in June. He said the addition of a CTLA-4 arm could differentiate it from PD-1/VEGF bispecifics, and that engineering to reduce Fc function is intended to mitigate toxicity while “still retain largely the efficacy by removing some of the safety liabilities,” based on preclinical data.

In closing remarks, Oyler said the company delivered “a very strong first quarter,” raised its full-year outlook, and sees the pipeline entering “a really critical phase of execution,” with hematology strength and an emerging solid tumor inflection point as programs advance into late-stage development.

About BeOne Medicines NASDAQ: ONC

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.